Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

BACKGROUND—: The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention compared with clopidogrel. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaduganathan, Muthiah, Harrington, Robert A., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920208/
https://www.ncbi.nlm.nih.gov/pubmed/27313282
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.003612

Ejemplares similares

Ejemplares similares